BR112019022321A2 - Tcr e peptídeos - Google Patents
Tcr e peptídeos Download PDFInfo
- Publication number
- BR112019022321A2 BR112019022321A2 BR112019022321-5A BR112019022321A BR112019022321A2 BR 112019022321 A2 BR112019022321 A2 BR 112019022321A2 BR 112019022321 A BR112019022321 A BR 112019022321A BR 112019022321 A2 BR112019022321 A2 BR 112019022321A2
- Authority
- BR
- Brazil
- Prior art keywords
- tcr
- peptides
- mhc
- binds
- peptide
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 1
- 108091008874 T cell receptors Proteins 0.000 abstract 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 1
- 102100022748 Wilms tumor protein Human genes 0.000 abstract 1
- 101710127857 Wilms tumor protein Proteins 0.000 abstract 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464452—Transcription factors, e.g. SOX or c-MYC
- A61K39/464453—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
a presente invenção se refere a um receptor de células t (tcr) que se liga a um peptídeo da proteína 1 de tumor de wilms (wt1) quando apresentado por um complexo principal de histocompatibilidade (mhc).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762489226P | 2017-04-24 | 2017-04-24 | |
US62/489,226 | 2017-04-24 | ||
PCT/EP2018/060477 WO2018197492A1 (en) | 2017-04-24 | 2018-04-24 | Tcr and peptides |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019022321A2 true BR112019022321A2 (pt) | 2020-05-26 |
Family
ID=62116393
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019022321-5A BR112019022321A2 (pt) | 2017-04-24 | 2018-04-24 | Tcr e peptídeos |
Country Status (15)
Country | Link |
---|---|
US (2) | US11597755B2 (pt) |
EP (1) | EP3615565A1 (pt) |
JP (2) | JP7328211B2 (pt) |
KR (1) | KR20200020681A (pt) |
CN (1) | CN110785432A (pt) |
AU (2) | AU2018259029B2 (pt) |
BR (1) | BR112019022321A2 (pt) |
CA (1) | CA3060343A1 (pt) |
EA (1) | EA201992536A1 (pt) |
MX (1) | MX2023012065A (pt) |
PH (1) | PH12019502400A1 (pt) |
SA (1) | SA519410362B1 (pt) |
SG (1) | SG11201909864TA (pt) |
TW (1) | TWI835730B (pt) |
WO (1) | WO2018197492A1 (pt) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9422547B1 (en) | 2015-06-09 | 2016-08-23 | Gigagen, Inc. | Recombinant fusion proteins and libraries from immune cell repertoires |
GB201803178D0 (en) * | 2018-02-27 | 2018-04-11 | Univ Oslo Hf | Specific binding molecules for htert |
CN109679917B (zh) * | 2018-09-30 | 2020-09-25 | 北京鼎成肽源生物技术有限公司 | 一种lrfft2细胞 |
GB201817821D0 (en) * | 2018-10-31 | 2018-12-19 | Ospedale San Raffaele Srl | TCR and peptides |
JP2022525099A (ja) * | 2019-03-11 | 2022-05-11 | フレッド ハッチンソン キャンサー リサーチ センター | 高アビディティwt1t細胞受容体とその使用 |
EP3941491A4 (en) | 2019-03-21 | 2023-03-29 | Gigamune, Inc. | ENGINEERED CELLS EXPRESSING ANTIVIRAL T-CELL RECEPTORS AND METHODS OF USE |
WO2021155518A1 (en) * | 2020-02-05 | 2021-08-12 | Tcrcure Biopharma Corp | Anti-hpv t cell receptors and engineered cells |
CN113621070A (zh) * | 2020-05-06 | 2021-11-09 | 华夏英泰(北京)生物技术有限公司 | 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用 |
CN112279908B (zh) * | 2020-10-23 | 2024-03-19 | 魏放 | 识别ebv抗原短肽的t细胞受体及其应用 |
CN112521484A (zh) * | 2020-12-03 | 2021-03-19 | 佛山市第一人民医院(中山大学附属佛山医院) | 结肠癌肿瘤特异tcr序列及其应用 |
JP2024512808A (ja) * | 2021-04-05 | 2024-03-19 | ヤンセン バイオテツク,インコーポレーテツド | Calr及びjak2t細胞受容体 |
WO2023081655A1 (en) * | 2021-11-02 | 2023-05-11 | Fred Hutchinson Cancer Center | T cell immunotherapy for hematologic malignancies having an sf3b1 mutation |
WO2023091420A2 (en) * | 2021-11-16 | 2023-05-25 | TCR2 Therapeutics Inc. | Compositions and methods for t cell engineering |
WO2023148494A1 (en) * | 2022-02-03 | 2023-08-10 | University College Cardiff Consultants Limited | Novel t-cell receptor |
WO2023193800A1 (zh) * | 2022-04-07 | 2023-10-12 | 恺兴生命科技(上海)有限公司 | 嵌合多肽及其应用 |
WO2024081915A1 (en) * | 2022-10-13 | 2024-04-18 | Ann And Robert H. Lurie Children's Hospital Of Chicago | Capture agents for detection of kawasaki disease |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9803351D0 (en) | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
US7655249B2 (en) | 1998-09-30 | 2010-02-02 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
GB0009760D0 (en) | 2000-04-19 | 2000-06-07 | Oxford Biomedica Ltd | Method |
GB0328363D0 (en) * | 2003-12-06 | 2004-01-14 | Imp College Innovations Ltd | Therapeutically useful molecules |
JP6433894B2 (ja) * | 2012-07-27 | 2018-12-05 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ | T細胞受容体の操作 |
JP6250288B2 (ja) * | 2013-01-30 | 2017-12-20 | 株式会社医学生物学研究所 | T細胞レセプターおよびその利用 |
TR201908404T4 (tr) * | 2013-11-22 | 2019-07-22 | Hutchinson Fred Cancer Res | İşlenmiş yüksek afinite insan t hücresi reseptörleri. |
ES2841274T3 (es) | 2014-08-04 | 2021-07-07 | Hutchinson Fred Cancer Res | Inmunoterapia con células T específica para WT-1 |
EP3277294B1 (en) * | 2015-04-01 | 2024-05-15 | Adaptive Biotechnologies Corp. | Method of identifying human compatible t cell receptors specific for an antigenic target |
-
2018
- 2018-04-24 TW TW107113927A patent/TWI835730B/zh active
- 2018-04-24 JP JP2020508082A patent/JP7328211B2/ja active Active
- 2018-04-24 EP EP18722426.6A patent/EP3615565A1/en active Pending
- 2018-04-24 US US16/605,561 patent/US11597755B2/en active Active
- 2018-04-24 BR BR112019022321-5A patent/BR112019022321A2/pt unknown
- 2018-04-24 AU AU2018259029A patent/AU2018259029B2/en active Active
- 2018-04-24 WO PCT/EP2018/060477 patent/WO2018197492A1/en active Application Filing
- 2018-04-24 CA CA3060343A patent/CA3060343A1/en active Pending
- 2018-04-24 SG SG11201909864T patent/SG11201909864TA/en unknown
- 2018-04-24 KR KR1020197034473A patent/KR20200020681A/ko not_active Application Discontinuation
- 2018-04-24 EA EA201992536A patent/EA201992536A1/ru unknown
- 2018-04-24 CN CN201880041641.8A patent/CN110785432A/zh active Pending
-
2019
- 2019-10-22 SA SA519410362A patent/SA519410362B1/ar unknown
- 2019-10-23 PH PH12019502400A patent/PH12019502400A1/en unknown
- 2019-10-24 MX MX2023012065A patent/MX2023012065A/es unknown
-
2023
- 2023-01-20 US US18/157,632 patent/US20240132569A1/en not_active Abandoned
- 2023-08-03 JP JP2023126659A patent/JP2023145687A/ja active Pending
-
2024
- 2024-06-07 AU AU2024203874A patent/AU2024203874A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2018197492A1 (en) | 2018-11-01 |
EA201992536A1 (ru) | 2020-03-05 |
SG11201909864TA (en) | 2019-11-28 |
CN110785432A (zh) | 2020-02-11 |
US20200123220A1 (en) | 2020-04-23 |
JP2020517308A (ja) | 2020-06-18 |
AU2018259029A1 (en) | 2019-12-12 |
SA519410362B1 (ar) | 2024-01-18 |
AU2024203874A1 (en) | 2024-08-29 |
US20240132569A1 (en) | 2024-04-25 |
JP7328211B2 (ja) | 2023-08-16 |
AU2018259029B2 (en) | 2024-03-07 |
PH12019502400A1 (en) | 2021-01-25 |
KR20200020681A (ko) | 2020-02-26 |
MX2023012065A (es) | 2023-10-23 |
US11597755B2 (en) | 2023-03-07 |
CA3060343A1 (en) | 2018-11-01 |
TWI835730B (zh) | 2024-03-21 |
EP3615565A1 (en) | 2020-03-04 |
JP2023145687A (ja) | 2023-10-11 |
TW201900675A (zh) | 2019-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019022321A2 (pt) | Tcr e peptídeos | |
BR112017023409A2 (pt) | ?célula t que expressa um receptor de célula t gama-delta (tcr) e um receptor de antígeno quimérico (car) | |
PH12017502190A1 (en) | T-cell receptor specific antibodies | |
CL2018003520A1 (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco. | |
CO2018010538A2 (es) | Anticuerpos específicos del receptor de poliovirus humano (rvp) | |
MX2018012897A (es) | Nuevos polipeptidos biespecificos contra cd137. | |
CL2020001181A1 (es) | Nuevos receptores de células t modificados genéticamente y terapias inmunológicas que emplean los mismos. | |
BR112016021004A2 (pt) | biblioteca de partículas; receptor de células t (tcr) isolado não natural; uso de uma biblioteca; método de obtenção de um receptor de células t que se liga especificamente a um antígeno de peptídeo; ácido nucleico; método de construção de uma biblioteca de partículas; método de obtenção de um receptor de células t que se liga especificamente a um antígeno de peptídeo; e partícula | |
BR112019018307A2 (pt) | Plataforma para identificação de peptídeos imunogênicos baseada em população | |
CO2020009644A2 (es) | Esteroides y conjugados de anticuerpos de los mismos | |
BR112016012358A2 (pt) | peptídios terapêuticos | |
BR112017020894A2 (pt) | imunoreceptores específicos claudina-18.2 e epítopos de células t | |
BR112018002386A8 (pt) | Anticorpo contra glypican-3 e aplicação do mesmo | |
PH12017501863A1 (en) | Bioconjugates and uses thereof | |
MX2018015285A (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco. | |
MX2018015277A (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco. | |
BR112016022727A2 (pt) | ?imunorreceptores específicos de claudina-6 e epítopos de células t | |
BR112018001683A2 (pt) | adenovírus recombinante, composição, uso de um adenovírus ou uma composição, e, adenovírus de símio não humano. | |
WO2020089433A3 (en) | Tcr and peptides | |
BR112017001242A2 (pt) | tratamento de câncer usando um receptor antigênico quimérico a cd33 | |
BR112016024494A2 (pt) | análogos de peptídeo com sonda(s) de aminoácidos ramificados | |
BR112019008345A2 (pt) | anticorpos monoclonais ligados à isoforma transmembrana cd160 | |
BR112016001782A2 (pt) | Proteína de fusão terapêutica | |
BR112018073136A2 (pt) | métodos para tratar doença autoimune usando células t alogênicas | |
BR112021016198A2 (pt) | Formulações de anticorpo anti-il-36r |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |